Comparative Pharmacology
Head-to-head clinical analysis: AMTURNIDE versus MINIZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMTURNIDE versus MINIZIDE.
AMTURNIDE vs MINIZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMTURNIDE is a combination of amiloride, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule. The combination produces additive diuretic and antihypertensive effects with reduced potassium loss.
Prazosin is a selective alpha-1 adrenergic antagonist that inhibits vascular smooth muscle contraction, reducing peripheral vascular resistance and blood pressure. Polythiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing sodium and water excretion, and reducing intravascular volume.
10 mg to 20 mg orally once daily, with or without food.
1-2 capsules orally twice daily; each capsule contains prazosin 0.5 mg and polythiazide 0.5 mg. Titrate based on blood pressure response.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10–14 hours); steady-state achieved within 2–3 days.
2-3 hours (prazosin component); prolonged in heart failure or renal impairment
Primarily renal excretion as unchanged drug (70%) and glucuronide conjugate (15%); biliary/fecal elimination accounts for 10%.
Renal: 90% (unchanged drug and metabolites); biliary/fecal: <10%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination